Omalizumab

'A monoclonal antibody used as a parenteral drug to treat severe asthma. It works by blocking your immune system''s natural response to allergic triggers that can lead to an acute asthma attack. This action on your immune system (specifically immunoglobulin E-IgE), helps keep your air passages open and, over time, it keeps your asthma in better control. This medication does not work immediately and should not be used for the quick relief of an acute asthma attack.'

Brands
XOLAIR
Adult Dose
Dose: 150 to 375 mg
Single Dose: 260 (262.5)
Frequency: As recommended.
Route: SC
Instructions: Should be given for 2 to 4 weeks, with dosing frequency determined by serum IgE level and weight.
Neonatal
Paedriatic
Characteristics
It belongs to Antibody pharmacological group on the basis of mechanism of action and also classified in Immune Globulin pharmacological group.
Contraindications
Omalizumab is contraindicated in conditions like Hypersensitivity to any component of product.
Effects
The severe or irreversible adverse effects of Omalizumab, which give rise to further complications include Alopecia, Thrombocytopenia, Allergic reactions.The symptomatic adverse reactions produced by Omalizumab are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Fatigue, Alopecia, Pruritus, Arthralgia, Hair loss, Dermatitis, Sinusitis, Alopecia, dizziness.
Indications
Omalizumab is primarily indicated in conditions like Severe persistent asthma.
Interactions
No data regarding the interactions of Omalizumab was found.
Interfrence
Elevated level of Serum IgE
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
'Omalizumab isn''t a rescue drug and isn''t intended for acute asthma attacks or status asthmaticus. Drug should not be discontinued abruptly. Patient should be monitored for severe hypersensitivity reactions.'
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.